Flexilev skal rulles ut i Europa.

Navamedic and Orion Corporation sign non-binding term sheet for Flexilev® in Europe
Oslo, 13. December 2023 - Navamedic ASA and Orion Corporation ("Orion") have
today signed a non-binding term sheet for a licensing- and supply agreement for
Flexilev®, including the Orafid dispenser, across Europe, not including Sweden,
Norway, Denmark, and Iceland, where Navamedic will market and sell the product.
Flexilev® is a novel prescription treatment for Parkinson's disease and was
added to Navamedic's product portfolio following the acquisition of Sensidose AB
in May 2023.
Orion and Navamedic have agreed to enter into a final agreement by the end of
the first quarter of 2024.

"The intended agreement with Orion to market and sell Flexilev® in Europe
represents a major milestone as part of the commercialization strategy for
Flexilev®. Since acquiring the product earlier this year, we have identified
several significant growth opportunities for Flexilev®, and this potential
agreement is one that can expand Navamedic's geographical reach outside of our
core market in the Nordics. Orion has long-standing experience in the field of
neurological diseases and has paved the way for Parkinson's disease treatment in
Europe, making it a strong commercial partner that matches Navamedic's ambition
for Flexilev®," says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.

Through the intended agreement, Orion will be granted the exclusive right to
market, distribute and sell Flexilev® in 27 countries in Europe, including the
"big five": Germany, France, Italy, Spain and the UK. Orion will be the
marketing authorization (MA) holder in their territory and assume all rights and
responsibilities as the MA holder. Furthermore, Orion will be granted the right
to use Navamedic's trademarks for the product.

The intended licensing agreement will consist of a non-refundable upfront
payment of 2mEUR to Navamedic, upon signature of the agreement. Additionally,
Navamedic is entitled to milestone payments of up to 3.5 mEUR upon reimbursement
approval in key countries, as well as royalties, and sales milestone payments.
Any potential future sales-based revenues to Navamedic will be dependent upon
the sales of Flexilev®.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680